Transfusions of granulocyte‐colony‐stimulating factor‐mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts
Authors:
- 1 July 1997
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 37 (7) , 737-748
Abstract
BACKGROUND: Granulocyte‐colony‐stimulating factor (G‐CSF) is a safe and effective agent for mobilization of neutrophils in normal donors, consistently resulting in cell yields per leukapheresis (LA) procedure that are superior to those with other agents. LA components also contain platelets, whose clinical relevance is unknown. STUDY DESIGN AND METHODS: This study describes the kinetics of and analyzes the factors determining the ANC and platelet count increments seen with each of three transfusions of granulocytes collected from HLA‐matched sibling donors receiving G‐CSF (n=10; maximum of 3 LA procedures/donor). The transfusions were given to recipients (n=10) on alternate days beginning. Day 1 after allogeneic bone marrow transplant (BMT). RESULTS: Significant, sustained increments in the recipient ANCs were observed after the transfusion of G‐CSF‐mobilized LA components. The mean peak posttransfusion increments in the ANCs were 1195, 729, and 631 per microL with transfusion of donor LA components on Days 1, 3, and 5, respectively. The length of time that the mean posttransfusion ANC was at or above the baseline (pretransfusion) value was 25 to 37 hours, depending on the post‐BMT day when the component was administered. No consistent relationship was observed between LA component granulocyte dose, baseline recipient ANC, or temperature elevation and post‐transfusion ANC increments. Large numbers of platelets (mean, 2.55 × 10(11)) were present in LA components, and this resulted in significant increments from baseline in the mean platelet count 1 hour after LA component transfusions. Between Days 1 and 7, the duration of severe neutropenia was shorter and the percentage of patients requiring nondonor platelet transfusions was less in study patients who received LA component transfusions than in a similar historical control group who did not. CONCLUSION: The transfusion of G‐CSF‐mobilized, HLA‐matched LA components to allogeneic BMT recipients resulted in significant and sustained increments in the ANC and the platelet count. Within the range examined, a relationship between neutrophil dose and an increment in the ANC was not demonstrated.Keywords
This publication has 66 references indexed in Scilit:
- Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trialThe Lancet, 1990
- Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemiaAmerican Journal of Hematology, 1983
- Prophylactic granulocyte transfusions during human bone marrow transplantationThe American Journal of Medicine, 1980
- A controlled study of the efficacy of granulocyte transfusions in patients with neutropeniaThe American Journal of Medicine, 1977
- Granulocyte transfusions in children using filter-collected cellsCancer, 1976
- The Acquisition of Granulocytes by Leukapheresis: A Comparison of Continuous Flow Centrifugation and Filtration Leukapheresis in Normal and Corticosteroid‐Stimulated DonorsTransfusion, 1976
- Granulocyte Transfusion: A Controlled Study in Patients with Acute Nonlymphocytic LeukemiaTransfusion, 1975
- GRANULOCYTE TRANSFUSIONS IN TREATMENT OF INFECTIONS IN PATIENTS WITH ACUTE LEUKÆMIA AND APLASTIC ANÆMIAThe Lancet, 1975
- White Blood Cell Transfusions for Control of Infections in Neutropenic PatientsTransfusion, 1975
- HISTOCOMPATIBILITY TESTING FOR LEUCOCYTE TRANSFUSIONThe Lancet, 1970